Trial Profile
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Eganelisib (Primary) ; Etrumadenant (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Gynaecological cancer; Ovarian cancer; Triple negative breast cancer
- Focus Adverse reactions
- Acronyms ARC-2
- Sponsors Arcus Biosciences
- 08 Oct 2021 Status changed from active, no longer recruiting to completed.
- 27 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2020 According to an Infinity Pharmaceuticals media release, data from this trial were presented during the 2020 San Antonio Breast Cancer Symposium (SABCS).